Breaking News, Collaborations & Alliances

Pluri and Bar-Ilan University Partner to Advance MAIT Cell Therapy for Solid Tumors

Aim to advance innovative allogeneic cell therapies targeting solid tumors.

Author Image

By: Charlie Sternberg

Associate Editor

Pluri Inc., a biotechnology company, has announced that the Israel Innovation Authority (IIA) will fund its collaboration with the Bar-Ilan University Research and Development Company Ltd., (BIRAD), the commercial arm of Bar-Ilan University, to support the continued development of Placental Mucosal Associated Invariant T (MAIT) cells for solid tumors.   MAIT cells are a unique type of T cell with potent anti-tumor activity. However, their clinical application has been hindered by challenges in...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters